Biogen To Launch Phase III Alzheimer’s Prevention Study
Executive Summary
The firm announced plans to begin a Phase III study of aducanumab to prevent or delay the onset of Alzheimer’s, but refused to discuss ongoing studies during its fourth quarter earnings call.